DUBLIN--(BUSINESS WIRE)--The "HP (High Potency) APIs Global Market Report 2020-30: Covid-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.
The global high potency APIs (HPAPI) market is expected to decline from $19.7 billion in 2019 to $18.5 billion in 2020 at a compound annual growth rate (CAGR) of -6%. The decline is mainly due to the focus on Covid-19 outbreak and its treatment across the globe, resulting in patients of other illnesses including cancer and other immunodeficiency diseases delaying their episodes of care and restrictions on trade and exports owing to the lockdown of countries that manufacture the drug. The market is then expected to recover and reach $24.1 billion in 2023 at a CAGR of 5.2%.
The rising number of cancer cases coupled with increasing sales of cancer drugs contributed to the growth of the high potency APIs market. Rising incidence of cancer is resulting in increasing R&D about anticancer drugs which in turn is propelling the demand for high potency APIs market. According to the World Health Organization's International Agency for Research (IARC) on Cancer report published in September 2018, the cancer burden increased to 18.1 million new cases and 9.6 million deaths in 2018, globally. Moreover, 70% of deaths from cancer occur in middle and low-income countries. Therefore, the growing incidence of cancer cases is projected to upsurge revenues for the high potency APIs market.
High investment requirements are anticipated to restrain the growth of the market over the coming years. The high potency APIs are cytotoxic, which are harmful to human cells. Moreover, they carry significant handling challenges including the requirement for specialized equipment to avoid cross-contamination, product protection, and to ensure environment and operator safety. Additionally, the requirement for appropriate process design and the constant evolution of technologies and industry standards, specialized containment facilities to facilitate the safety of the employees requires huge financial support. Therefore, large investment requirement acts as a major challenge for the growth of the high potency APIs market.
The companies dealing in the high potency APIs market are focusing on strategies such as production facility expansion and mergers & acquisitions to maintain their position in the competitive business environment. For instance, in 2017, Piramal Enterprises, an India based pharmaceuticals company, invested $55 million to enhance the capabilities of its five API manufacturing plants in India and U.S.A. In the following year, in October 2018, Lonza, a Switzerland based specialty contract development and manufacturing organization (CDMO) in biopharma industry, announced the expansion of its potent API (HPAPI) capacity by adding two new sites in order to support of antibody-drug conjugates (ADC) payload manufacturing.
In August 2019, Permira Funds, a U.K based global investment firm, acquired Cambrex Corporation for USD 2.4 million.Through the acquisition Permira Funds will provide financial support to Cambrex Corporation for its expansion of product manufacturing and analytical testing services. Cambrex Corporation is a life sciences company that offers products and services for small molecule active pharmaceutical ingredients with its headquarters in U.S.A.
Major players in the high potency APIs (HPAPI) market are Eli Lily and Company, Novartis AG, Bristol-Myers Squibb Company, Roche Diagnostics Ltd., Sanofi, Hospira, Inc., BASF SE, Covidien plc, Boehringer Ingelheim GmbH and Merck & Co., Inc.
Key Topics Covered
1. Executive Summary
2. High Potency APIs Market Characteristics
3. High Potency APIs Market Size And Growth
3.1. Global High Potency APIs Historic Market, 2015-2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global High Potency APIs Forecast Market, 2019-2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market
4. High Potency APIs Market Segmentation
4.1. Global High Potency APIs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- Innovative HPAPI
- Generic HPAPI
4.2. Global High Potency APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- Synthetic HPAPI
- Biotech HPAPI
4.3. Global High Potency APIs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- Harmonal Disorder
- Other Therapeutic Applications (Respiratory Disorders, CVD, Diabetes, Cosmetology, and Erectile Dysfunction)
5. High Potency APIs Market Regional And Country Analysis
5.1. Global High Potency APIs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global High Potency APIs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- AstraZeneca plc
- BASF SE
- Bayer AG
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Carbogen Amcis AG
- Covidien plc
- Eli Lily & Company
- GlaxoSmithKline PLC
- Hospira Inc.
- Merck & Co. Inc.
- Mylan, Inc.
- Novartis AG
- Pfizer Inc.
- Roche Diagnostics Ltd.
- Sigma Aldrich Corporation
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/96amsj